Psychiatric uses of topiramate : what is the current evidence?

dc.contributor.authorJoubert, Pierre M.
dc.date.accessioned2008-10-17T12:11:06Z
dc.date.available2008-10-17T12:11:06Z
dc.date.created2008-10-08
dc.date.issued2008-06
dc.description.abstractTopiramate enhances gamma-amino-butyric acid effects, has antiglutaminergic effects, and is a state-dependent sodium channel blocker. It is registered as an adjunctive treatment for epilepsy but is not registered for psychiatric indications. Nevertheless, it may be useful beyond its initial indication, considering the promising literature on which I report below. However, much more research evidence is needed to establish sufficient scientific justification for prescribing it routinely for psychiatric purposes.en_US
dc.identifier.citationJoubert, PM 2008, 'Psychiatric uses of topiramate : what is the current evidence?', South African Journal of Psychiatry, vol. 14, no. 2, pp. 44-50. [http://www.hmpg.co.za/journaldetail.php?journalno=4]en_US
dc.identifier.issn1608-9685
dc.identifier.urihttp://hdl.handle.net/2263/7597
dc.language.isoenen_US
dc.publisherHealth and Medical Publishing Groupen_US
dc.rightsHealth and Medical Publishing Groupen_US
dc.subjectTopiramateen_US
dc.subject.lcshPsychiatry
dc.subject.lcshTopiramate
dc.subject.lcshEpilepsy
dc.titlePsychiatric uses of topiramate : what is the current evidence?en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Joubert_Psychiatric(2008).pdf
Size:
162.69 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.39 KB
Format:
Item-specific license agreed upon to submission
Description: